Goldman Sachs Group, Inc. (The) set a €82.00 ($95.35) price objective on Sanofi SA (EPA:SAN) in a report issued on Friday. The firm currently has a neutral rating on the stock.

Other analysts have also issued research reports about the stock. J P Morgan Chase & Co set a €90.00 ($104.65) price objective on shares of Sanofi SA and gave the stock a neutral rating in a research note on Tuesday, August 1st. S&P Global set a €90.00 ($104.65) price objective on shares of Sanofi SA and gave the stock a neutral rating in a research note on Monday, July 31st. Sanford C. Bernstein set a €90.00 ($104.65) price objective on shares of Sanofi SA and gave the stock a neutral rating in a research note on Monday, July 31st. Jefferies Group LLC set a €87.00 ($101.16) price objective on shares of Sanofi SA and gave the stock a neutral rating in a research note on Thursday, August 24th. Finally, BNP Paribas set a €85.00 ($98.84) price objective on shares of Sanofi SA and gave the stock a neutral rating in a research note on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of €87.24 ($101.44).

Shares of Sanofi SA (EPA:SAN) opened at €79.60 ($92.56) on Friday. Sanofi SA has a 52 week low of €70.94 ($82.49) and a 52 week high of €92.97 ($108.10).

TRADEMARK VIOLATION NOTICE: “Sanofi SA (SAN) PT Set at €82.00 by Goldman Sachs Group, Inc. (The)” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/sanofi-sa-san-pt-set-at-82-00-by-goldman-sachs-group-inc-the-2/1684190.html.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.